'New animal drug evaluation' presentation slideshows

A Perspective on Risk Analysis for the GMP Initiative

A Perspective on Risk Analysis for the GMP Initiative. H. Gregg Claycamp, Ph.D., CHP Center for Veterinary Medicine Office of New Animal Drug Evaluation hclaycam@cvm.fda.gov May 22, 2003. Outline. The Premise and Questions Basics of Risk Analysis

839 views • 49 slides

U.S. Food and Drug Administration

387 views • 27 slides

702 views • 26 slides

Effectiveness Evaluation for Therapeutic Drugs for Food Animals

Effectiveness Evaluation for Therapeutic Drugs for Food Animals. Emily Smith, DVM Office of New Animal Drug Evaluation (ONADE) Division of Therapeutic Drugs for Food Animals. What are therapeutic drugs?.

523 views • 25 slides

Aquaculture

Aquaculture. Jennifer Matysczak , VMD Leader, Aquaculture Drugs Team US Food and Drug Administration Center for Veterinary Medicine Office of New Animal Drug Evaluation. Topics that will be discussed. Uniqueness of aquaculture drugs Judicious use of antimicrobials

416 views • 22 slides

Regulating Animal Drugs

Regulating Animal Drugs . Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine. Regulating Animal Drugs. Protect the Public Health by ensuring safe and effective animal drugs reach the market unsafe and ineffective animal drugs do not reach the market.

382 views • 21 slides

Labeling Issues

Labeling Issues. Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM. Labeling of Approved New Animal Drugs :. Key Way We Communicate to Users: What we learned about the drug during the pre-approval (investigational) phase

374 views • 18 slides

U.S. Food and Drug Administration

251 views • 6 slides